‘Welcome addition’
Dupilumab is “a welcome addition to what we do,” said Philip Katz, MD, a professor of medicine in the division of gastroenterology at Weill Cornell Medicine in New York. The publication of this “pivotal” trial provides reassurance about its safety and effectiveness for EoE, he added.
“Dupilumab, or Dupixent, is going to be used in my practice for people who are refractory to both PPIs and topical steroids,” Dr. Katz, who was not involved in the research, said in an interview.
However, it will take practice to know how best to use the drug, and its high cost may make some payers reluctant to cover it, Dr. Katz added.
The study was funded by Sanofi and Regeneron. Dr. Dellon has reported financial relationships with multiple pharmaceutical companies, including Regeneron and Sanofi US. Dr. Katz has reported financial relationships with Phantom Pharmaceuticals, AstraZeneca, and Braintree Laboratories.
A version of this article first appeared on Medscape.com.